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Carbogen breathing with nicotinamide improves the oxygen status of
tumours in patients
VM Laurence, R Ward, IF Dennis and NM Bleehen
MRC Unit and University Department ofClinical Oncology, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK.
S_ry Nicotinamide and carbogn breathing are both effective radiosenusers in experimental tumour
models and are even more effecte combination. This study was to investigate the feasiiity of usin the
agents in combination in patients and to measure thmeir effect on tumour oxygenation. Twelv patients with
advanced malignant disea wer treated with 4-6 g of oral nicotinamide (NCT) in tablet formulation. Ten of
these 12 patients breathed cabogen (95% oxygen, 5% cabon dioxide) for up to 20min at presumed peak
plasma NCT concentration (Cp,) and had tumour oxygen partial pressure (p02) measured using the
EppendorfpO2) histograph. The mean Cp, values were 82, 115 and 150 zgmrl for NCT doses of4, 5 and 6
g respectively and were dose dependent. The time ofc,.k was independent ofdose with an overall mean of2.4
h (range 0.7-4 h). NCT toxicity occurred in 9 out of 12 patients and was mild in all but one; carbogen was
well tolerated in all patients. Following NCT only two patients had significant rises (P<0.05) in tumour
median During breathing, eight out of ten patients had early highly significant rises in pO2
(P<0.0001), of which six continued to rise or remained in plateau until completion of gas breathing. Six
patients had hypoxc pre tment vahles less than 5 mmHg, which were completely abolshed in three and
reduced in two during breathinng In concluon, the combination of NCT and carbogen breathing
was generally well tolerated and gave rise to substantial rises in tumour P02 which were maintained
throughout gas breathing. These results should encourage further study of this potentially useful combination
of agents as radiosensitisers in the clinic.
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Strategies to improve tumour oxygenation during radiation
treatment remain an important area of laboratory and
clinical research. Despite positive findings in some trials of
hyperbaric oxygen and radiation sensitsers, these agents have
failed to become part of routine clinical practice to date
(Overgaard, 1992). This has been partly because of inade-
quate patient numbers in many of the trials, but also to do
with problems of compliance in the case of hyperbaric
oxygen and unacceptable toxcity in the case of sensitisers
(Henk, 1981; Dische, 1985). Current approaches should now
address the issue of tumour repopulation (Dische, 1991) as
well as the existence in tumours of both acute and chronic
hypoxia (Coleman, 1988).
Combining nicotinamide with carbogen breathing (95%
oxygen, 5% carbon dioxide) and accelerated hyperfrac-
tionated radiation regimens (ARCON) is one such approach
currently being evaluated in Europe. Both nicotinanude and
carbogen breathilg (aimed at overcoming acute and chronic
hypoxia respectively) can enhance radiosensitivity and imp-
rove the therapeutic ratio in murine tumours when used
alone (Horsman et al., 1987; Horsman et al., 1989; Rojas,
1991). Maximum enhancement is achieved when the agents
are used in combination and has been demonstrated with
both single and multifraction radiation treatments (Kiellen et
al., 1991; Chaplin et al., 1993; Simon et al., 1993). By deliver-
ing the radiation in an accelerated regimen, in an attempt to
prevent tumour repopulation, even further enhancement can
be achieved (Rojas, 1992). Clinical studies using combina-
tions of these agents are now under way in patients, but their
exact modes of action and optimum ways of delivery remain
under investigation.
The B vitamin derivative nicotnamide appears to improve
radiosensitivity primarily by overcoming acute hypoxia which
may occur as a result of the transient closure of oxygen and
nutrent supplying vessels within the tumour microcirulation
(Horsman et al., 1988, 1989; Chaplin et al., 1990). Although
it has been previously used with little toxicity in daily doses
of up to 12 g in the treatment of benign disease (Zackheim,
1981), its use in patients with neoplastic disease is novel. Its
pharmacokinetics has been measured in man at doses up to 6
g (Stratford et al., 1992; Horsman et al., 1993a), but its
optimum dose, formulation and timing of administration in
relation to radiation treatment are not yet fully established.
Early studies suggested that radiosensitisation in murine
tumour models occurs only at doses which would-be toxic in
man (Brown, 1992), but a recent study has suggested that
enhancement is independent of dose provided that radiation
is given when nicotinamide plasma concentration is at its
peak (Horsman et al., 1993a) and that doses of 6 g in man
should be enough to produce tumour sensitisation.
Normobaric oxygen and carbogen breathing are well
established in animal models as radiation sensitsers (Rojas,
1991). They are thought to overcome hypoxia by increasng
the dissolved oxygen partial pressure (p02) and increasing the
intracapllary haemoglobin saturation, thus maing more
oxygen available to chronically depnved hypoxc tumour
cells located beyond the maximum diffusion distance of
oxygen (Kruuv et al., 1967). The preirradiation breathing
tim (PIBT) appears to be a critical factor in radiosensitisa-
tion, with optimum enhancement occurring within short
defid time periods in murine tumours (Siemann et al.,
1977). However, its importance is diminished by the concur-
rent use of nicotinamide (Chaplin et al., 1993). Some of the
previous studies of carbogen and oxygen breathing in man
may have failed owing to the use of extended periods of
PIBT (Keresteci and Rider, 1973; Rubin et al., 1979). How-
ever, in one randomised controlled study in patients with
carcinoma of the cervix breathing normobaric oxygen for
5-10 min before inradiation, both local recurrence and
overall survival were improved by the addition of oxygen
(Bergsjo and Kolstad, 1968).
On the assumption that both nicoinamide and arbogen
breathing may improve radiosensitisation by their action on
tumour hypoxia, there has been some attempt to date to
measure the effects of the agents on tumour P02 distribution.
Measurement of tumour P02 distribution was previously
hampered by the lack of a rehable direct method. The com-
puterised Eppendorfp0 histograph oxygen microelectrode
system has now become established as a safe, reproducible
Correspondence: V Laurence
Received 12 July 1994; revised 23 January 1995; accepted 5 February
1995*cdi -- dbw P0
VM Lauence et i
and relatively non-invasive method for measuring pO2 in
accespible tumours and normal ssues (Kaflinowski et al.,
1990; Vaupel et al., 1991). This method has been used to
study tumour p02 distribution changes in animal models
following treatment with either nicotinamide or carbogen.
Rises in p02 following nicotinamide treatment have been
shown in only one study to date (Lee and Song, 1992),
whereas others have shown no change (Kelleher and VaupeL
1993). Significant rises have been shown following treatment
with carbogen breathing (Horsman et al., 1993b; Vitu-Loas et
al., 1993). In man, tumour p02 rises have been demonstrated
during carbogen breathing in two studies to date (Falk et al.,
1992; Martin et al., 1993) but pO2 has not been measured
following treatment with nicotinamide or the combination.
In the current study, we have measured changes in tumour
p02 distribution in patients with advanced malignant disease
following nicotinamide administion and during subsequent
carbogen breathing. In addition, we have studied
nicotnamide pharmacokinetcs and the toxicty of the com-
bined treatment.
Matk and os
Patient characteristics
Twelve patients were entered into the study, of whom ten
received the combination of nicotinamide and carbogen
breathing before irradiation and had measurements of
tumour pO2 distribution performed. Two patients received
nicotinamide alone and were eligible for toxicity and phar-
macokinetic asse nt. Table I shows the characteristics and
tumour details of the treated patients. All had advanced
recurrent or metastatic histologically proven malignancy
requiring palliative irTadiation, with accessible tumours of an
adequate size to obtain a satisfactory number ofp02 readings
without tissue trauma. Tumours were not cystic, haemorr-
hagic or too firm for P02 measurements to be performed.
Only one had been previously irradiated in the site used for
p2 measurements (no. 5). All patients were of WHO perfor-
mance status <2 and had no serious cardiac or respiratory
illness. All had haemoglobin values above 11 g dl'-. Patients
were defined as smokers if they had smoked at any time
during the past 5 years. The protocol was approved by the
lcal ethical committee and written informed consent was
obtained from all patients.
Nicotinanide a&ninistration
Al patients received oral nicotinamide at a dose of 4-6 g as
500 mg tablets (Larkhall Natural Health, UK). It had been
our intention to treat all patients with a sandard dose of6 g,
but following unexpected acute toxicity in the second patient
we modified our dose to 4 g until further experience had been
gained. Tablets were taken 3-4 h after a light breakfast. No
cigarettes, food or drink other than water were alowed after
breakfast until completion of carbogen breathing.
Carbogen breathing
Carbogen breathing was commenced as close to the
estimated time of peak plasma nicotinamide concentration as
possible. Published data suggested that this would be at
around 90 min (Stratford et al., 1992) and this time was used
for the initial patients. However, as large individual variation
was found, approximate nicotinamide concentrations were
measured diretly in the clinic in six patients (see Phar-
macokinetic assessment below) and carbogen breathing was
commenced at the time ofindividually estimated peak plasma
nicotinamide concentrations. During carbogen breathing
patients wore an air-tight scuba-diving face mask covering
the nose and mouth (SOS Products) and were in control of
holding the mask in place. The inhaled carbogen (95%
oxygen, 5% carbon dioxide; from British Oxygen) was
delivered to the face mask using a closed system with
regulated flowrate of 4-5 Imin'I through an anaesthetic
ambubag and two-way valve (supphed by Intrsurgical).
Exhaled gas was removed using elephant tubing connected
between the valve and a window to the outside. Patients were
asked to breathe carbogen for as long as they were able to do
so for up to 20min. On completion of breathing carbogen,
all patients were treated with palliative irradiation.
Pharmacokinetic assessment
Serial 5 ml venous blood samples were collected from a
heparinised 22 G cannula (Venflon, Viggo, UK) at regular
time points after nicotinamide administration. Urine was also
collcted for 24 h. Plasma and urine nicotinamide concentra-
tions were determined using a method of high-performance
liquid chromatography (HPLC) analysis based on the proce-
dure descrbed by De Vries and Stratford (De Vries et al.,
1980; Stratford et al., 1992). Briefly, 200yI of plasma was
added to 400 1z of acetonitrile containing 25pgml-l Ro-31-
602 as an internal standard, and after vortexing the sample
was centrifuged (9500g, 5 min). A 50pil aliquot of the super-
natant was diluted with 150pzl of mobile phase and injected
onto the HPLC system. Separations were achieved on a
Nova-Pak C,i (8 mm x 10cm Radial Pak cartridge) with a
mobile phase of 25% acetonitrile, and 75% of an aqueous
solution of 2 mM sulphosucante 1 mM trimethylamin,
20mM orthophosphoric acid and 5 mM sodium dihydrogen
orthophosphate at a flow rate of 2mlmin'. Nicotinamide
was det by UV absorbance at 254 nm and quantified by
peak area with reference to calibration standards using
Waters Expert-Ease software V2.1.
Having found wide variability in the time of peak plasma
nicotinamide concentration in initial patents, we subse-
quently used a rapid detection method in the clinic. Plasma
nicotinamide concentration was estimated usng an LKB UV
spectrophotometer. This is an approximate method which
does not distinguish between nicotnamide and its
metabolites but nonetheless gives an indication of increasing
and decreasing blood concentrations of detectable com-
pounds. Briefly, plasma was obtained by centfugation of
1 ml blood samples at 7500 g for 3 min. A I ml aliquot of
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Table I Patient and tumour characteristics
Smoker Tmnour
Patient Age Height Weight Hb in last vohone
no. Sex (years) (m) (kg) (g dl-1) 5 years Tumour site Tumour histology (CMa)
I M 57 - 74 11.7 Y Skin met AC caccum 4
2 M 72 1.70 77 14.9 N Neck node met SCC bladdkr 8
3 M 68 1.77 79 14.4 N Chestwall met SCCkidney 11
4 F 58 1.58 73 12.1 Y Neck node met SCLC 23
5 F 64 1.58 75 13.9 N Groin node met SCC cervix 29
6 M 57 1.70 81 12.3 Y Suprasteralmass met SCLC 6
7 F 66 1.58 59 11.0 N Skin met AC stomnach 57
8 M 71 1.75 78 12.5 N Groin node met SCC bronchus 28
9 F 68 1.60 52 11.1 N Breast rec AC breast 10
10 M 42 1.80 60 11.5 Y Neck node met SCC bronchus 64
11 M 86 1.71 56 na Y Chestwal mt AC bronchus 104
12 F 57 1.62 84 14.8 N Neck node met AC breast 113
met, metastatic rc, recurrent, SCC, squamous ccl cino .-Ma; SCLC, small cell hlg cancer, AC, adenocarcinona.dn -q~wS - ^ bUrn
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dried acetonitrile was added to 200 IlI of plasma and the
mixture was vortexed and then centrifuged for a further
3 min at 7500g. The supernatant was transferred to a clean
glass cuvette and measured at 260 nm. When sample absor-
bance levels showed a plateau or decline it was assumed that
peak plasma nicotinamide concentration had been reached.
The renainder of the initial 5 ml blood samples from these
patients were stored on ice for subsequent HPLC analysis
and comparison with spectrophotometer results.
Assessment oftoxicity
Patients all had an initial full history and physical examina-
tion performed with particular attention to measurement of
the tumour in which pO2 measurements were to be per-
formed. Resting pulse rate, blood pressure and arterial
oxygen saturation (measured by pulse oximeter supplied by
Omeda) were performed before and at 15 min intervals after
nicotinamide administration and until completion of car-
bogen breathing. Any unexpected symptoms or change in
vital signs were noted. On completion of the radiation treat-
ment pulse rate and blood pressure were monitored every 4 h
for 24 h. Patients were assessed for early toxicity by history
and examination before discharge at 24 h and reassessed in
the clinic 3-4 weeks after the procedure.
Tumour oxygen measurements
Tumour oxygen partal pressure pO2 was measured using the
computerised KIMOC 6650 Eppendorfp2 histograph as
previously described in detail (Vaupel et al., 1991). In brief,
the polarographic electrode system was calibrated for 15 min
in buffered sterile physiological saline with air and 100%
nitrogen before and after each series of measurements. After
initial calibration a 22 G intravenous cannula (Venflon) was
inserted into or near the tumour following the subcutaneous
injection of 2 ml of local anaesthetic (lignocaine 2% without
adrenaline). Tumour temperature was measured using a
tissue-implantable thermocouple microprobe (Physitemp)
with BAT 10 data display system and was programmed into
the histograph so that all p2 readings were corrected for
temperature. The microelectrode probe was then inserted into
the tumour through the cannula in order to protect the
membrane of the cathode. The eectrode was allowed to
stabiise and the set of measurements then taken. The probe
was programmed to move forwards in steps of 1 mm
immediately followed by a step of 0.3 mm backwards in
order to minimise tsue compression artefacts.
The track length and number oftracks taken were individ-
ually wlcted according to tumour size, and sets of radings
were obtained from across the maximum diameter of the
tumour. Patients ained supine in a warm and comfortable
position during the procedure. Sets of measurements were
performed before nicotinamide administration, at etimated
peak plasma nicotinamide concentration (unmediately before
arbogen breathing) and then at 3-4 time points during
arbogen breathing to obtain a time course. Each individual
measurement was displayed on the histograph as it was taken
and sets were then presented as frequency histograms.
Evaluation ofdata andstatistical anolysis
Sets ofp02 measurements from each patient were transferred
from the Eppendorf histograph to a Macintosh SE/30 and
analysed using Statview software (Abacus Concepts) to
obtain median values, inter-percentile ranges and percentages
of vahles less than 10, 5 and 2.5 mmHg for individual
patients. Statistal analysis was by the non-parametnc
Mann-Whitney U-test to assess the sign of any
changes in p02 distribution after treatment with nicotinamide
and durng carbogen breathing. Intra- and inter-tumour
heterogeneity were compared using analysis of variance and
usng the median pO2 of each indiidual track as the
parameter of oxygenation. Three time intervals were chosen
based on data availabiality and compared using Snedecor's
variance ratio test (Moroney, 1990). Pharmacokinetic data
were analysed using Kaleidagraph software (Albeck) for the
calculations of means, standard errors and correlation co-
efficients.
Reasd
Nicotinmide ph/nnacokinetics
Pharmacokinetic data were analysed from 12 patients and are
shown in Table II; four patients received a dose of 4 g, three
received 5 g and five received 6 g. There was wide variation
between patients in both peak plasma cotinamide concent-
ration and time to reach it. The mean peak plasma
nicotinamide concentrations were 82, 115 and 150pgml-'
for doses of 4, 5 and 6g respectively, the overall mean
± l(s.e.) being 115 (± 10)pigml-'. There was a linear rela-
tionship between peak plasma nicotinamide concentration
and nicotinamide dose expressed either in g, mgkg-' or
gm-2 (correlation coefficients, R = 0.73, 0.68 and 0.73
respectively). Figure 1 shows the relationship between
administered nicotinamide dose in grams and peak plasma
nicotinamide concentration. In contrast, no relationship was
found between dmid nicotinamide dose and the time
of peak plasma nicotinamide concentration, which had an
inter-patient range of 0.7-4 h with a mean ( s.e.) of 2.4
(± 0.3) h.
We were particularly concerned to begin carbogen
breathing as near to the time of peak plasma nicotinamide
concentration as possible. Having found marked variation in
this time in the initial patients we then used the spect-
rophotometric assay in six subsequent patients. We assumed
that peak nicotinamide concentration had been reached when
a plateau or fall in UV absorption was detected. At this stage
a set of oxygen measurements was performed and then car-
bogen breathing commenced. A time lag between the true
time of the peak and commencement of carbogen thus
inevitably occurred. Figure 2 shows the comparative profiles
of the perctages of peak plasma nicotinamide concentra-
tions in the Six patients as measured by the two different
assays and their relationship to the time of carbogen
breathing. It demonstrates that the rapid spectrophotometric
assay gave a reasonable indication of the peak in all except
one patient (no. 9). Of the five patients who breathed car-
bogen four (80%) had mean nicotinamide plasma concentra-
tions (as measured by subsequent HPLC analysis) during gas
breathing which were within 10% of the peak. In contrast, if
a standard 90min time to reach the peak had been assumed
throughout the study, only 33% of the patients would have
had nicotinamide plasma concentrations within 10% of the
peak at the commencement of carbogen breathing (data not
shown). Overall, the mean plasma concentration of
nicotinamide during carbogen breathing was within 20% of
peak plasma nicotinamide concentration in eight out of ten
patients.
Toxicity associated with nicotinamide
After nicotinamide administration 9 out of 12 patients
suffered from some toxicity (Table I). Diastolic blood pres-
sure fell in three patients (> 15 mmHg diastolic), of whom
two were asymptomatic and one had accompanying mild
diziness. Five patients noticed flushing, one accompaied by
mild nausea, and three had mild headaches. One patient with
a long-standing history of asymptomatic hypertension, con-
currently receiving bendrofluazide medication, suffered
signifcant toxicity at the time of peak nicotinamide concent-
ration, with profound hypotension resulting in a transient
cardiorespiratory arrest. He quickly regained consciousness
but ained relatively bradycardic and hypotensive for
several hours. He recovered completdy with no further
sequelae.VM Laurence et a
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Carbogen breathing
Of the 12 patients in the study, two did not breathe car-
bogen. The patient in whom major toxicity occurred was
obviously unable to complete the study, and patient no. 11
was able to tolerate nicotinamide but judged to be too frail
to breathe carbogen. Carbogen breathing was well tolerated
by all remaining patients. It was performed for between 15
and 20 min in all except one (no 1), who was only able to
complete 10 min of gas breathing. One patient removed his
mask for 4 min after 13 min (no. 6) and then recommenced
breathing again for a further 3 min. During carbogen
breathing the mean time to reach 100% arterial oxygen
saturation was 2.35 min (range 0.5-6 min).
Toxicity associated with combined treatment
Following radiation treatment all patients were assessed at
24 h and at 3-4 weeks. No obvious increase in normal tissue
toxicity was noted.
Twnour oxygenation
Sets of tumour p02 measurements were obtained in ten
patients. Between 30 and 150 measurements were performed
per set of readings using typically 3-4 tracks. Table III
shows the number of readings per set and the parameters of
tumour oxygenation in terms of the median P02 value in
mmHg and the percentage of values<5 mmHg obtained
during each set of readings. We have chosen to present the
value of % < 5 mmHg to represent hypoxia as only one
patient had >1% of readings of <2.5 mmHg before treat-
ment (Hall, 1987). Table IV shows the estimates of variance,
using median pO2 as the parameter of oxygenation, before
treatment, at presumed peak nicotinamide concentration and
during carbogen breathing. At all three time points there was
greater variation of oxygenation between tumours than
within tumours, confirming that despite wide inter-percentile
ranges per set an adequate number of readings hr J been
taken to exclude any bias (Nordsmark et al., 1994).
Figure 3 shows the changes in median P02 and the
interpercentile ranges (10-90%) for each set of
measurements performed in all patients. Following
nicotinamide only two patients had significant rises in
median tumour P02 (P<0.05) compared with pretreatment.
During carbogen breathing, and comparing P02 distributions
with those obtained after nicotinamide, nine out of ten
patients had highly significant rises in median tumour P02
(P<0.0001). These rises occurred within 10 min of commen-
cing carbogen in all except one patient (no. 4) and continued
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to rise significantly or remain in plateau in all except two
(nos. 10 and 12). Of the six patients with pretreatment values
of less than 5 mmHg, these had been completely abolished in
three and were reduced in two during carbogen breathing.
Patient no. 5 was the only patient who had previously been
irradiated in the measured site and was also the only patient
to show no significant rise in tumour median P02-
Dimscio
The aim of this study was to investigate whether combining
treatment with nicotinamide and carbogen breathing altered
P02 distribution in accessible tumours of patients with
advanced malignant disease. In addition, data were obtained
on changes in P02 after nicotinamide alone, nicotinamide
pharmacokinetics and toxicity of the combined treatment.
The nicotinamide pharmacokinetic data confirmed and
extended those for man already in the literature. Following
doses of 4-6g in tablet formation (51-108mgkg-') the
magnitude of peak concentration and plasma clearance were
consistent with previous findings on normal volunteers (Strat-
ford et al., 1992; Horsman et al., 1993a) and were both
dose dependent. The time to reach peak plasma concentra-
tion was widely variable and was independent of dose, as in
Stratford's study using the same formulation, but unlike
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Horsman's results using a capsule formulation, after which
the time to reach peak concentration occurred predictably
within 45 min of ingestion. There is clear evidence in an
animal system that maximum radiosensitisation by
nicotinamide occurs at the time of peak plasma concentra-
tion and surprisingly appears to be independent of the mag-
nitude of the peak (Horsman et al., 1993a). The efforts made
in this study to deliver carbogen at the time of peak
nicotinamide concentration were largely successful. The spec-
trophotometric assay was cumbersome but allowed
reasonable assessment of the time of the peak. Nonetheless, a
capsule or rapid release formulation with a more predictable
time of peak concentration would clearly be an advantage.
There has been some debate about the required dose of
nicotinamide in humans which might achieve significant
radiosensitisation without toxicity (Brown, 1992). Initial
studies suggested that optimum sensitisation could only be
achieved in murine tumours with intraperitoneal (i.p.) doses
of over 500 mg kg-l which were thought to translate into a
dose in man which would be unacceptable in terms of tox-
icity (Horsman et al., 1987). In a recent study of the com-
parative pharmacokinetics of nicotinamide in mouse and
man, oral doses of 6 g in man gave rise to similar peak
plasma levels as 171 mg kg-' i.p. nicotinamide in mice (Hors-
man et al., 1993a), a dose which produced maximal enhance-
ment of radiation damage in the mouse tumours provided
that the radiation was delivered at the time of peak drug
level. Thus assuming that a similar mechanism occurs in
man, a 6 g dose should be adequate -to ensure enhancement
of radiosensitisation provided that the radiation can be given
at the time of peak plasma drug levels. This is a substantially
smaller dose than was originally thought to be required.
Although 6 g is thought to be a safe dose in man, there
still remain questions about potential toxicity. Neither study
of nicotinamide pharmacokinetics in man reported major
toxicity in healthy volunteers, although single instances of
migraine and nausea and vomiting were reported (Stratford
D0 et al., 1992; Horsman et al., 1993a). Nicotinamide has been
e ecxtensively and safely used in repeat dosage of up to 6 g in
the treatment of a number of benign conditions (Zackheim,
1981), but in the current study of patients with malignant
disease most complained of minor side-effects. The hypoten-
E sive episode occuring at peak plasma nicotinamide concent-
E ration in one patient in the study is a cause for greater
0 concern. It is likely that this event was related to his concur-
rent diagnosis of hypertension and antihypertensive medica-
tion, but caution still needs to be maintained until further
experience is gained of this drug in patients with malignant
0s disease.
The precise mode of action of nicotinamide as a radiosen-
r4 sitiser in animal tumour models remains unclear. It is
thought to be a result of improved tumour oxygenation, as
0 shown indirectly by a reduction in ['4Cjmisonidazole binding
(Horsman et al., 1988) and specifically a decrease in acute
hypoxia as demonstrated using the histological mismatch
technique (Chaplin et al., 1990). The observed effects of
K. nicotinamide on blood perfusion and tumour P02 as
measured directly by microelectrodes have not been consis-
V tent. Data from one study demonstrated increases in tumour
oxygen distribution in the FSaII mouse tumour model fol-
lowing treatment with 500 mgkg-1 i.p. nicotinamide in
E association with increased blood perfusion and increased 2 radiosensitivity (Lee and Song, 1992). In another study using 0_
a different tumour model, significant increases in hypoxic
values (<10 mmHg) were found despite an improvement in
tumour blood flow (Kelleher and Vaupel, 1993).
In contrast, carbogen breathing has been found to increase
E median P02 and to decrease hypoxic values in several animal
._a studies (Horsman et al., 1993b; Vitu-Loas et al., 1993). Of
particular importance has been our previous demonstration
in RIF-I tumours grown in C3H mice that, while
nicotinamide produced no significant rise in tumour P02
distribution, carbogen breathing gave rise to large increases
in median P02. Maximum increases occurred when
nicotinamide and carbogen breathing were combined (Honess
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Table IV Estimates of variance, using median P02 as oxygenation parameter
Sum of Degrees of Variance
squares freedom estimate F P-value
Pretreatment (n = 10)
Between patients 11385 9 1265
Between tracks in a patient 14828 29 511 2.47 0.01 <P<0.05
Post-NCr (n= 8)
Between patients 7585 7 1084
Between tracks in a patient 3478 15 232 4.7 0.005<P<0.01
During carbogen breathing at 5-10 min
(n= 10)
Between patients 26071 9 2897 9.3 P<0.001
Between tracks in a patient 5625 18 313
F= Snedecor's variance ratio. P-value obtained from F-distrubiton tables, using the tabulated degrees of freedom.
et al., 1994). These observations are consistent with the
findings of maximum enhancement of radiosensitisation
occurring after combining the agents (Kjellen et al., 1991).
In man there have been no other published studies of the
measurement of tumour P02 distribution following combined
treatment with nicotinamide and carbogen breathing. The
findings of greater between- than within-tumour hetero-
geneity at three time points support the impression of wide
individual variation between tumours and make pooling of
individual patient data irrelevant. Each individual was
therefore assessed separately, and nine out of ten showed
significant rises in tumour oxygen distribution. As in our
previous study of carbogen breathing alone (Falk et al.,
1992), we found a wide range of change in median p02 with
elimination of some but not all values ofp02 below 5 mmHg.
The rises in median pO2 tended to be of greater magnitude
than in the previous study and were sustained until 15 min
and over in the majority of our patients, whereas in the
previous study a fall in median tumour pO2 occurred in all
patients between 12 and 18min.
Our current results suggest that the combination of
nicotinamide and carbogen breathing may give rise to greater
improvements in tumour hypoxia than carbogen breathing
alone, and in particular may result in a sustained rise rather
than a rise followed by a progressive fall. These results are
supported by experimental animal data. Thus Chaplin et al.
(1993) have shown that the influence of the length ofthe pre-
irradiation breathing time of carbogen on radiosensitivity
was diminished by the concurrent use of nicotinamide, fol-
lowing which hypoxia was apparently abolished. Our
findings, overall, support the results in experimental tumour
models of a greater reduction in tumour hypoxia after the
use of the combined agents compared with either agent
alone. In addition, the combination appears to be effective
over a longer time period than carbogen alone, which in the
clinic would ensure less risk of missing the time of presumed
tumour radiosensitisation.
In conclusion, we have treated ten patients with advanced
malignant disease with the combination of oral nicotinamide
and carbogen breathing before palliative radiotherapy and a
further two patients received nicotinamide alone. Side-effects
were generally mild except for one patient who suffered from
a major toxic event. Despite being unable to demonstrate
marked changes in tumour oxygen distribution close to peak
plasma nicotinamide concentration and therefore at assumed
optimum time for radiosensitisation, large and highly
significant rises in median tumour P02 were demonstrated
during carbogen breathing which were sustained for at least
15 min. Although these changes in P02 cannot be shown to
be occurring in the milieu of the radioresistant hypoxic cells,
our results are encouraging and should stimulate further
clinical studies of this potentially highly effective combination
of agents in order to establish whether the impressive
therapeutic gains seen in animal models will be repeatable in
man.
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